TherapeuticsMD, Inc. Financial Ratios
TXMD|FY2024 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2024 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2024)
Return on Equity
-35.1%
Profit Margin
-789.4%
Net Income / Revenue
Asset Turnover
0.03
Revenue / Total Assets
Equity Multiplier
1.33
Total Assets / Equity
Composite: -35.1% (reported: -35.1%)
Profitability
Liquidity
Current Ratio
2.37
Quick Ratio
2.37
Solvency
Interest Coverage
-138.54
Efficiency
Asset Turnover
0.03
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2024 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
+31.2%
-205.8pp YoY
Earnings include a notable portion of accrual components.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.